Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Exp Cell Res ; 360(2): 264-272, 2017 11 15.
Article in English | MEDLINE | ID: mdl-28899658

ABSTRACT

The 37kDa/67kDa laminin receptor (LRP/LR) serves various physiological and pathological roles such as enhancing tumour-related processes including metastasis, angiogenesis, cellular viability and telomerase activation in cancerous cell lines. The present study investigates the effect of siRNA mediated downregulation of LRP/LR on pancreatic cancer (AsPC-1) and neuroblastoma (IMR-32) cells. MTT and BrdU assays revealed that siRNA mediated downregulation of LRP resulted in a significant reduction in cell viability and cell proliferation. In addition, knock-down of LRP resulted in phosphatidylserine externalization, diminished nuclear integrity and significantly enhanced caspase-3 activity, which is indicative of apoptosis. LRP downregulation resulted in a significant increase in caspase-8 activity in IMR-32 cells and enhanced caspase-8 and 9 activity in AsPC-1 cells. These data recommend siRNA mediated knock-down of LRP as a potential therapeutic avenue for the treatment of pancreatic cancer and neuroblastoma.


Subject(s)
Apoptosis/genetics , Caspases/metabolism , Neuroblastoma/genetics , Pancreatic Neoplasms/genetics , Receptors, Laminin/genetics , Apoptosis/drug effects , Enzyme Activation/drug effects , Enzyme Activation/genetics , Gene Expression Regulation, Neoplastic/drug effects , Gene Knockdown Techniques , Humans , Neuroblastoma/pathology , Pancreatic Neoplasms/pathology , RNA, Small Interfering/pharmacology , Tumor Cells, Cultured
2.
BMC Cancer ; 16(1): 917, 2016 11 24.
Article in English | MEDLINE | ID: mdl-27884119

ABSTRACT

BACKGROUND: Cancer has become a global burden due to its high incidence and mortality rates, with an estimated 14.1 million cancer cases reported worldwide in 2012 particularly as a result of metastasis. Metastasis involves two crucial steps: adhesion and invasion, and the non-integrin receptor; the 37-kDa/67-kDa laminin receptor precursor/ high affinity laminin receptor (LRP/LR) has been shown to be overexpressed on the surface of tumorigenic cells, thus being implicated in the enhancement of these two crucial steps. The current study investigated the role of LRP/LR on the aggressiveness of pancreatic cancer (AsPC-1) and neuroblastoma (IMR-32) cells with respect to their adhesive and invasive potential. METHODS: AsPC-1 and IMR-32 cells were utilized as the experimental cell lines for the study. Cell surface LRP/LR levels were visualised and quantified on the experimental and control (MCF-7) cell lines via confocal microscopy and flow cytometry, respectively. Total LRP/LR levels in the cell lines were assessed by Western blotting and the adhesive and invasive potential of the above-mentioned cell lines was determined before and after supplementation with the anti-LRP/LR specific antibody IgG1-iS18. Statistical significance of the data was confirmed via the use of the two-tailed student's t-test and Pearson's correlation coefficient. RESULTS: Flow cytometry revealed that AsPC-1 and IMR-32 cells displayed significantly higher cell surface LRP/LR levels in comparison to the MCF-7 control cell line. However, Western blotting and subsequent densitometric analysis revealed that all three tumorigenic cell lines displayed no significant difference in total LRP/LR levels. The treatment of AsPC-1 and IMR-32 cells with IgG1-iS18 caused a significant reduction in the adhesive and invasive potential of the cells to laminin-1 and through the ECM-like Matrigel™, respectively. Pearson's correlation coefficients indicated a high correlation, thus suggesting a directly proportional relationship between cell surface LRP/LR levels and the adhesive and invasive potential of AsPC-1 and IMR-32 cells. CONCLUSION: These findings suggest that through the interference of the LRP/LR-laminin-1 interaction, the anti-LRP/LR specific antibody IgG1-iS18 may act as an alternative therapeutic tool for the treatment of metastatic pancreatic cancer and neuroblastoma.


Subject(s)
Antibodies, Monoclonal/pharmacology , Cell Adhesion/drug effects , Immunoglobulin G/immunology , Neuroblastoma/prevention & control , Pancreatic Neoplasms/prevention & control , Receptors, Laminin/antagonists & inhibitors , Apoptosis/drug effects , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Blotting, Western , Cell Movement/drug effects , Cell Proliferation/drug effects , Humans , Neoplasm Invasiveness , Neuroblastoma/metabolism , Neuroblastoma/pathology , Pancreatic Neoplasms/metabolism , Pancreatic Neoplasms/pathology , RNA, Messenger/genetics , Real-Time Polymerase Chain Reaction , Receptors, Laminin/immunology , Receptors, Laminin/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Tumor Cells, Cultured
3.
Mol Med ; 22: 664-673, 2016 Oct.
Article in English | MEDLINE | ID: mdl-27611822

ABSTRACT

Cancer is a highly complex disease that has become one of the leading causes of death globally. Metastasis, a major cause of cancer deaths, requires two crucial events known as adhesion and invasion. The 37kDa/67kDa laminin receptor [laminin receptor precursor/high-affinity laminin receptor (LRP/LR)] enhances these two steps, consequently aiding in cancer progression. In this study, the role of LRP/LR in adhesion and invasion of early (SW-480 & HT-29) and late (DLD-1) stage colorectal cancer cells has been investigated. Western blotting revealed that early and late stage colorectal cancer cells contained significantly higher total LRP/LR levels compared to poorly invasive MCF-7 breast cancer control cells. Flow cytometry revealed that all three stages of colorectal cancer displayed significantly higher cell surface LRP/LR levels. Furthermore, upon treatment of the colorectal cancer cells with the anti-LRP/LR specific antibody IgG1-iS18, adhesion to laminin-1 was significantly reduced in all three stages. Each stage's invasive potential was determined using the Matrigel™ invasion assay, which revealed that invasion is significantly impeded in all three colorectal cancer stages when the cells are incubated with IgG1-iS18. In addition, Pearson's correlation coefficients propose that both total and cell surface LRP/LR levels are directly proportional to the adhesive and invasive potential of all three stages of colorectal cancer. Hence, these findings indicate the potential for the use of the IgG1-iS18 antibody as a promising therapeutic tool for colorectal cancer patients of early and late stage.

4.
Expert Opin Ther Pat ; 25(5): 567-82, 2015 May.
Article in English | MEDLINE | ID: mdl-25747044

ABSTRACT

INTRODUCTION: The 37/67 kDa high-affinity laminin receptor (laminin receptor precursor/laminin receptor, LRP/LR) is a multi-faceted cellular receptor. It plays a vital role in the malignancy of various cancer types where it is seen to contribute to invasion, adhesion, apoptosis evasion and angiogenesis. Furthermore, it has been found to play an important role in facilitating the processes leading to neurotoxicity in Alzheimer's disease (AD). Various therapeutic options targeting this receptor have been patented with the outlook on application for the treatment/prevention of these diseases. AREAS COVERED: The various roles that LRP/LR plays in cancer, AD and infectious diseases caused by viruses and bacteria have been examined in detail and an overview of the current patented therapeutic strategies targeting this receptor is given. EXPERT OPINION: Molecular tools directed against LRP/LR, such as antibodies and small interfering RNA, could prove to be effective in the prevention of metastasis and angiogenesis while inducing apoptosis in cancers. Moreover, these strategies could also be applied to AD where LRP/LR is seen to facilitate the production and internalization of the neurotoxic Aß peptide. This review provides a comprehensive overview of the mechanisms by which LRP/LR is involved in eliciting pathogenic events, while showing how the use of patented approaches targeting this receptor could be used to treat them.


Subject(s)
Drug Design , Molecular Targeted Therapy , Receptors, Laminin/drug effects , Ribosomal Proteins/drug effects , Alzheimer Disease/drug therapy , Alzheimer Disease/physiopathology , Animals , Antineoplastic Agents/pharmacology , Humans , Neoplasms/drug therapy , Neoplasms/pathology , Patents as Topic , RNA, Small Interfering/administration & dosage , Receptors, Laminin/metabolism , Ribosomal Proteins/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...